What is the 13F Pro Quality Score for BOLD?

13F Pro ranks Boundless Bio, Inc. (BOLD) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View BOLD's current score at https://13fpro.ai/research/BOLD (free sign-up required for the full ranking).

Which hedge funds own the most BOLD stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of BOLD include FMR, CITADEL ADVISORS, SECTORAL ASSET MANAGEMENT. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/BOLD as soon as new 13F filings post.

Where does 13F Pro source BOLD data?

All Boundless Bio, Inc. fundamentals and ownership data come directly from SEC EDGAR. Boundless Bio, Inc. files with the SEC under CIK 1782303. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is BOLD in?

Boundless Bio, Inc. (BOLD) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is BOLD research updated on 13F Pro?

BOLD's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Boundless Bio, Inc.(BOLD)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1782303 BOLD stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

BOLD Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Boundless Bio, Inc. (BOLD), a Healthcare sector company. BOLD is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), Boundless Bio, Inc. reports net income of $-13.6M, free cash flow of $-15.0M. Top institutional holders of BOLD by reported 13-F value include FMR, CITADEL ADVISORS, SECTORAL ASSET MANAGEMENT, based on the most recent SEC filings. BOLD trades on the Nasdaq exchange and files with the SEC under CIK 1782303. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BOLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Boundless Bio, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-13.6M

Free Cash Flow

Q1 2026

$-15.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+11.0% YoY

$-58.2MFY 2025

FY23 $-49.4MFY24 $-65.4MFY25 $-58.2M

Operating Income

+13.3% YoY

$-63.6MFY 2025

FY23 $-54.8MFY24 $-73.3MFY25 $-63.6M

EPS (Diluted)

+32.5% YoY

$-2.60FY 2025

FY23 $-40.65FY24 $-3.85FY25 $-2.60

Total Assets

-23.9% YoY

$157.1MFY 2025

FY23 $129.9MFY24 $206.4MFY25 $157.1M

Op. Cash Flow

+23.3% YoY

$-46.7MFY 2025

FY23 $-46.9MFY24 $-60.8MFY25 $-46.7M

Metric	FY 2025	FY 2024	FY 2023
Net Income	$-58.2M +11.0%	$-65.4M -32.2%	$-49.4M
Operating Income	$-63.6M +13.3%	$-73.3M -33.7%	$-54.8M
EPS (Diluted)	$-2.60 +32.5%	$-3.85 +90.5%	$-40.65
Total Assets	$157.1M -23.9%	$206.4M +58.9%	$129.9M
Operating Cash Flow	$-46.7M +23.3%	$-60.8M -29.8%	$-46.9M

AI Insight: BOLD Financial Trends

Boundless Bio's equity base has eroded 52% from $179M to $86M over eight quarters as the pre-revenue biotech burns through cash with no offsetting income.

• Equity has declined steadily every quarter, falling from $179M in Q2 2024 to $86M in Q1 2026 — a $93M reduction.

• Operating losses narrowed modestly from -$19M in Q2 2024 to -$14M in Q1 2026, suggesting slight expense discipline.

• Operating cash outflow improved from -$16M in Q2 2024 to -$10M by Q3–Q4 2025, but reversed to -$15M in Q1 2026.

⚠ Equity runway at current burn rate implies depletion within ~6 quarters; no revenue yet to offset losses.

⚠ Op CF deteriorated to -$15M in Q1 2026 after two quarters at -$10M — a potential re-acceleration of cash burn.

AI Insight: BOLD Ratio Trends

All return metrics have deteriorated sharply with ROE worsening from -37.9% in Q2 2024 to -62.8% in Q1 2026, signaling accelerating capital erosion.

• ROE deteriorated from -37.9% in Q2 2024 to -62.8% in Q1 2026, a worsening of roughly 25 percentage points.

• ROIC declined from -43.3% in Q2 2024 to -67.0% in Q1 2026, reflecting consistently poor returns on invested capital.

• ROA has fluctuated between -31.9% and -39.7%, showing no stabilization trend across the observed periods.

⚠ TTM ROE of -64.8% and ROIC of -70.2% suggest capital burn is accelerating — monitor cash runway closely.

⚠ OpMargin, NPM, and D/E are entirely absent; lack of profitability and leverage data limits full financial assessment.

Get alerted when BOLD's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Boundless Bio, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of BOLD

FMR LLC
$3.0M2,695,455 sh
CITADEL ADVISORS LLC
$1.5M1,342,131 sh
SECTORAL ASSET MANAGEMENT INC
$746.4K678,574 sh
Stonepine Capital Management, LLC
$657.5K597,682 sh
VANGUARD CAPITAL MANAGEMENT LLC
$656.9K597,192 sh
WELLINGTON MANAGEMENT GROUP LLP
$611.9K556,233 sh
RENAISSANCE TECHNOLOGIES LLC
$438.9K399,000 sh
Alyeska Investment Group, L.P.
$330.0K300,000 sh
RBF Capital, LLC
$220.0K200,000 sh
Ensign Peak Advisors, Inc
$206.3K187,500 sh

Fund	Value	Shares
FMR LLC	$3.0M	2,695,455
CITADEL ADVISORS LLC	$1.5M	1,342,131
SECTORAL ASSET MANAGEMENT INC	$746.4K	678,574
Stonepine Capital Management, LLC	$657.5K	597,682
VANGUARD CAPITAL MANAGEMENT LLC	$656.9K	597,192
WELLINGTON MANAGEMENT GROUP LLP	$611.9K	556,233
RENAISSANCE TECHNOLOGIES LLC	$438.9K	399,000
Alyeska Investment Group, L.P.	$330.0K	300,000
RBF Capital, LLC	$220.0K	200,000
Ensign Peak Advisors, Inc	$206.3K	187,500

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put BOLD on your watchlist

Track score changes the day Boundless Bio, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is BOLD a good stock to buy?

13F Pro's AI-powered analysis of Boundless Bio, Inc. (BOLD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for BOLD are available on the BOLD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own BOLD?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling BOLD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Boundless Bio, Inc.'s investment landscape.